Quattro Financial Advisors’s AstraZeneca AZN Stock Holding History

Quattro Financial Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,300	Closed	-$553K	–	83
2025 Q1	$553K	Buy	3,300 +1,150	+53%	+$166K	0.19%	59
2024 Q4	$432K	Buy	2,150 +1,650	+330%	+$231K	0.11%	68
2024 Q3	$11.9M	Sell	500 -2,000	-80%	-$323K	3.37%	10
2024 Q2	$390K	Hold	2,500	–	–	0.1%	58
2024 Q1	$339K	Buy	2,500 +2,466	+7,253%	+$327K	0.1%	63
2023 Q4	$337K	Sell	34 -2,466	-99%	-$321K	0.12%	69
2023 Q3	$339K	Hold	2,500	–	–	0.15%	66
2023 Q2	$358K	Sell	2,500 -5,000	-67%	-$736K	0.14%	66
2023 Q1	$1.04M	Hold	7,500	–	–	0.43%	40
2022 Q4	$1.02M	Hold	7,500	–	–	0.41%	42
2022 Q3	$823K	Hold	7,500	–	–	0.33%	46
2022 Q2	$991K	Hold	7,500	–	–	0.34%	42
2022 Q1	$995K	Sell	7,500 -5,000	-40%	-$600K	0.34%	50
2021 Q4	$1.46M	Hold	12,500	–	–	0.51%	43
2021 Q3	$1.51M	Hold	12,500	–	–	0.4%	46
2021 Q2	$1.43M	Hold	12,500	–	–	0.38%	48
2021 Q1	$1.29M	Buy	+12,500	New	+$1.26M	0.29%	57

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quattro Financial Advisors's AZN Position: Q2 2025 in Review

Quattro Financial Advisors sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 3,300 shares — an estimated $553K sold.

Quattro Financial Advisors first reported a position in AZN in Q1 2021 and held it in 17 quarters. The position peaked at $11.9M in Q3 2024. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

Quattro Financial Advisors reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
Quattro Financial Advisors sold 3,300 AstraZeneca shares in Q2 2025, an estimated $553K.
Quattro Financial Advisors first reported a position in AstraZeneca in Q1 2021 and held it in 17 quarters.
Quattro Financial Advisors's AstraZeneca position peaked at $11.9M in Q3 2024.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Quattro Financial Advisors's 13F filing for Q2 2025, filed 21 Jul 2025.